179 related articles for article (PubMed ID: 32738737)
1. The global landscape of drug development for kidney cancer.
Trapani D; Curigliano G; Alexandru E; Sternberg CN
Cancer Treat Rev; 2020 Sep; 89():102061. PubMed ID: 32738737
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
3. Practice and progress in kidney cancer: methodology for novel drug development.
Rini BI; Weinberg V; Small EJ
J Urol; 2004 Jun; 171(6 Pt 1):2115-21. PubMed ID: 15126769
[TBL] [Abstract][Full Text] [Related]
4. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology.
Tobert CM; Uzzo RG; Wood CG; Lane BR
Urol Oncol; 2013 Oct; 31(7):1316-20. PubMed ID: 22264501
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of renal cell cancer: A comprehensive review.
Sánchez-Gastaldo A; Kempf E; González Del Alba A; Duran I
Cancer Treat Rev; 2017 Nov; 60():77-89. PubMed ID: 28898679
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
10. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib for the treatment of kidney cancer.
Abdelaziz A; Vaishampayan U
Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
[TBL] [Abstract][Full Text] [Related]
12. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
Gupta S; Fishman M
Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
[TBL] [Abstract][Full Text] [Related]
13. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
14. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
Reed JP; Posadas EM; Figlin RA
Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
Homicsko K; Berthold DR
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
[TBL] [Abstract][Full Text] [Related]
16. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
17. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
18. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in small molecule therapies for renal cell carcinoma.
Song M
Eur J Med Chem; 2017 Dec; 142():383-392. PubMed ID: 28844802
[TBL] [Abstract][Full Text] [Related]
20. Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?
Mehrazin R; Tsao CK; Sfakianos J; Galsky MD
Urol Oncol; 2016 May; 34(5):221-4. PubMed ID: 26997518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
